Rodman & Renshaw initiated coverage of TuHURA Biosciences (HURA) with a Buy rating and $11 price target TuHURA is focused on developing treatments to overcome primary and acquired resistance to checkpoint inhibitors by using its proprietary technology platform, Immune FxTM, the analyst tells investors in a research note. The firm says the company’s strategy leverages bacterial proteins to activate the immune system avoids common issues like the toxicity and infections often linked to using attenuated bacteria for cancer therapy.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HURA:
- TuHURA Biosciences to Acquire Kineta, Inc. in 2025
- TuHURA Biosciences enters definitive merger agreement to acquire Kineta
- HURA, SVR, HUC: 3 Commodity ETFs to Hedge against Inflation
- TuHURA Biosciences Advances in Cancer Immunotherapy Innovations
- TuHURA Biosciences announces upcoming milestone targets
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue